POS1100 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL SUSPICION RED FLAGS IDENTIFICATION BY A SYSTEMATIC LITERATURE REVIEW AND MULTIDISCIPLINARY EXPERT CONSENSUS
Authors: R. Solans-Laqué, M. Cid, R. Blanco, M. Blanco-Aparicio, I. Garcia-Moguel, E. Arismendi-Nuñez, A. Noblejas Mozo, F. Perez-Grimaldi, M. Labradror-Horrillo, C. Domingo-Rivas, G. Espigol-Frigole, F. Sanchez-Toril, F. Ortiz-Sanjuan, J. M. Alvaro-Gracia, Í. Rúa-Figueroa
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, histologically characterized by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis of EGPA is often challenging due to its rarity, heterogeneous and multiorgan clinical presentation, and the overlapping with other vasculitis or eosinophilic disorders. The identification of suspicion signals of EGPA addresses a fundamental practical barrier in achieving timely diagnosis for patients with this rare but potentially devastating disease. <h3>Objectives:</h3> To identify a comprehensive and evidence-based checklist of signs, symptoms and laboratory parameters reported to precede the diagnosis of EGPA that can be used as red flags, raising the suspicion and prompt the performance of appropriate confirmatory tests. <h3>Methods:</h3> A systematic literature search strategy was developed to identify signs, symptoms and laboratory abnormalities that should raise the suspicion of a possible EGPA. GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology was used to assess the quality of the scientific evidence supporting each criterion. A multidisciplinary nominal group consensus approach (including rheumatologists, internal medicine specialists, pulmonologists, and allergists) was established for the development of the expert consensus. Red flags identified as suspicion signals for EGPA were categorized by organ system, manifestation, and laboratory test to facilitate rational, evidence-based clinical review of patients presenting with eosinophilia. <h3>Results:</h3> A total of 382 records were identified and reviewed, and 85 studies were included in the literature review. From these 85 publications a total of 214 items were assessed and 40 red flags were identified as relevant to raise a suspicion of EGPA. As the publications were derived from observational studies the GRADE level of evidence was low. Using these 40 red flags, an evidence-based clinical checklist tool was developed for use in routine practice to raise EGPA suspicion in patients with eosinophilia (peripheral blood eosinophil count &gt;1 x 10<sup>9</sup>/L, with no treatment that could explain an alteration of this value) (Table 1). <h3>Conclusion:</h3> Systematic literature review, multidisciplinary expert consensus rating and GRADE methodology has enabled, for the first time, the identification of a comprehensive set of red flags that could be used to raise a suspicion for EGPA, providing clinicians with an evidence-based checklist tool that can be integrated into their routine practice. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Funded by GSK. <h3>Disclosure of Interests:</h3> Roser Solans-Laqué GSK, CSL VIFOR, Menarini, Mariona Cid GSK, Ricardo Blanco Abbvie, Pfizer, Roche, Lilly, UCB, Bristol-Myers, GSK, Janssen, Novartis, MSD, Marina Blanco-Aparicio Astra-Zeneca, GSK, Sanofi, Chiesi, Faes, Ismael Garcia-Moguel Novartis, Astra-Zeneca, Teva,GSK, Sanofy Genzyme, Chiesi, Pfizer, Orion Pharma, Leti, Allegy therapeutics, ALK-Abello, Ebymar Arismendi-Nuñez GSK, Astra-Zeneca, MSD, NOvartis, Begro-Pharma, Sanofy-Genzyme, Ana Noblejas Mozo CSL, Vifor, Gebro-Pharma, Astra Zeneca, CSL Vifor, Francisco Perez-Grimaldi Astra-Zeneca, GSK, Sanofi, Novartis, Chiesi, Teva Esteve, menarini, Boehringer Ingelheim, Moises Labradror-Horrillo Astra-Zeneca, GSK, Novartis, Sanofi-Pasteur, GSK, Chistian Domingo-Rivas Almirall, Astra-Zenca, Boehringer-Ingelheim, Chiesi, GSK, Menarini, NOvartis, Pfizer, Georgina Espigol-Frigole GSK, Fernando Sanchez-Toril ALK, Astra-Zeneca, Chiesi, Faes, Novartis, Pfizer, Teva, Boehringer Ingelheim, Sanofi, Francisco Ortiz-Sanjuan GSK, Grunenthal, Jose-Maria Alvaro-Gracia GSK, Abybie, Astra Zeneca, Galapagos, Gilead, Pfizer, Novartis, Lilly, MSD, UCB, Íñigo Rúa-Figueroa GSK.